- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02997228
Kombinasjonskjemoterapi, Bevacizumab og/eller Atezolizumab ved behandling av pasienter med mangelfull DNA-mismatch reparasjon Metastatisk tykktarmskreft, COMMIT-studien
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT)-studie: En randomisert fase III-studie av mFOLFOX6/Bevacizumab/Atezolizumab-kombinasjon versus enkeltmiddel atezolizumab i førstelinjebehandlingen av pasienter med mangelfull DNA-feilreparasjon (dMMR) Instabilitet-høy (MSI-H) metastatisk tykktarmskreft
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Studieoversikt
Status
Intervensjon / Behandling
- Annen: Quality-of-Life Assessment
- Biologisk: Bevacizumab
- Legemiddel: Fluorouracil
- Fremgangsmåte: Magnetic Resonance Imaging
- Annen: Questionnaire Administration
- Fremgangsmåte: Biospecimen Collection
- Legemiddel: Atezolizumab
- Legemiddel: Oxaliplatin
- Fremgangsmåte: Computed Tomography
- Legemiddel: Leucovorin
- Fremgangsmåte: Positron Emission Tomography
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To determine the efficacy, based on progression-free survival (PFS), of fluorouracil, oxaliplatin, and leucovorin calcium (modified [m]FOLFOX6)/bevacizumab plus atezolizumab (combination) as compared to single agent atezolizumab.
SECONDARY OBJECTIVES:
I. To compare the overall survival. II. To compare the objective response rates (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
III. To determine the safety profiles of single agent atezolizumab and the combination of mFOLFOX6/bevacizumab/atezolizumab in patients with mismatch-repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
IV. To determine the duration of response. V. To determine the duration of stable disease. VI. To determine the rate of progression-free survival (PFS) at 12 months. VII. To evaluate the disease control rate (complete response [CR] + partial response [PR] + stable disease [SD]) at 12 months.
TRANSLATIONAL OBJECTIVE:
I. To bank tissue and blood samples for other future correlative studies from patients enrolled on the study.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I (CLOSED TO ACCRUAL 6/4/2020): Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with or without positron emission tomography (PET) or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM II: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM III: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
After completion of study treatment, patients are followed up every 8 weeks for 18 months, and then every 12 weeks for up to 5 years.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Kingman, Arizona, Forente stater, 86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Jonesboro, Arkansas, Forente stater, 72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
-
California
-
Anaheim, California, Forente stater, 92806
- Kaiser Permanente-Anaheim
-
Baldwin Park, California, Forente stater, 91706
- Kaiser Permanente-Baldwin Park
-
Bellflower, California, Forente stater, 90706
- Kaiser Permanente-Bellflower
-
Berkeley, California, Forente stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Concord, California, Forente stater, 94520
- John Muir Medical Center-Concord
-
Fontana, California, Forente stater, 92335
- Kaiser Permanente-Fontana
-
Harbor City, California, Forente stater, 90710
- Kaiser Permanente South Bay
-
Irvine, California, Forente stater, 92618
- Kaiser Permanente-Irvine
-
Los Angeles, California, Forente stater, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Forente stater, 90034
- Kaiser Permanente West Los Angeles
-
Marysville, California, Forente stater, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Forente stater, 95355
- Memorial Medical Center
-
Ontario, California, Forente stater, 91761
- Kaiser Permanente-Ontario
-
Orange, California, Forente stater, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Forente stater, 92868
- Saint Joseph Hospital - Orange
-
Panorama City, California, Forente stater, 91402
- Kaiser Permanente - Panorama City
-
Riverside, California, Forente stater, 92505
- Kaiser Permanente-Riverside
-
Sacramento, California, Forente stater, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Forente stater, 95817
- University of California Davis Comprehensive Cancer Center
-
Salinas, California, Forente stater, 93901
- Salinas Valley Memorial
-
San Diego, California, Forente stater, 92120
- Kaiser Permanente-San Diego Zion
-
San Diego, California, Forente stater, 92108
- Kaiser Permanente-Rio San Diego
-
San Marcos, California, Forente stater, 92078
- Kaiser Permanente-San Marcos
-
Walnut Creek, California, Forente stater, 94598
- John Muir Medical Center-Walnut Creek
-
Whittier, California, Forente stater, 90602
- Presbyterian Intercommunity Hospital
-
Woodland Hills, California, Forente stater, 91367
- Kaiser Permanente-Woodland Hills
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Forente stater, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, Forente stater, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, Forente stater, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, Forente stater, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Forente stater, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Forente stater, 80920
- Memorial Hospital North
-
Denver, Colorado, Forente stater, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Forente stater, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Forente stater, 80204
- Denver Health Medical Center
-
Denver, Colorado, Forente stater, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Forente stater, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver, Colorado, Forente stater, 80210
- AdventHealth Porter
-
Englewood, Colorado, Forente stater, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Forente stater, 80113
- Swedish Medical Center
-
Fort Collins, Colorado, Forente stater, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Forente stater, 80528
- Cancer Care and Hematology-Fort Collins
-
Golden, Colorado, Forente stater, 80401
- National Jewish Health-Western Hematology Oncology
-
Greeley, Colorado, Forente stater, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, Forente stater, 80631
- Banner North Colorado Medical Center
-
Littleton, Colorado, Forente stater, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Forente stater, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland, Colorado, Forente stater, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, Forente stater, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Thornton, Colorado, Forente stater, 80260
- National Jewish Health-Northern Hematology Oncology
-
Wheat Ridge, Colorado, Forente stater, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Danbury, Connecticut, Forente stater, 06810
- Danbury Hospital
-
Hartford, Connecticut, Forente stater, 06102
- Hartford Hospital
-
Meriden, Connecticut, Forente stater, 06451
- Midstate Medical Center
-
New Britain, Connecticut, Forente stater, 06050
- The Hospital of Central Connecticut
-
Norwich, Connecticut, Forente stater, 06360
- William Backus Hospital
-
-
Delaware
-
Millville, Delaware, Forente stater, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Forente stater, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Forente stater, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Forente stater, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20002
- Kaiser Permanente-Capitol Hill Medical Center
-
-
Florida
-
Fort Lauderdale, Florida, Forente stater, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Forente stater, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Gainesville, Florida, Forente stater, 32610
- UF Health Cancer Institute - Gainesville
-
Jacksonville, Florida, Forente stater, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, Forente stater, 32803
- AdventHealth Orlando
-
-
Georgia
-
Albany, Georgia, Forente stater, 31701
- Phoebe Putney Memorial Hospital
-
Athens, Georgia, Forente stater, 30607
- University Cancer and Blood Center LLC
-
Augusta, Georgia, Forente stater, 30912
- Augusta University Medical Center
-
Augusta, Georgia, Forente stater, 30901
- Augusta Oncology Associates PC-D'Antignac
-
Augusta, Georgia, Forente stater, 30909
- Augusta Oncology Associates PC-Wheeler
-
Newnan, Georgia, Forente stater, 30265
- CTCA at Southeastern Regional Medical Center
-
-
Idaho
-
Boise, Idaho, Forente stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Forente stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Forente stater, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Forente stater, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Forente stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forente stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forente stater, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Forente stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Forente stater, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Forente stater, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Forente stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Forente stater, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Forente stater, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Forente stater, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Forente stater, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Forente stater, 60612
- University of Illinois
-
Chicago, Illinois, Forente stater, 60612
- Rush MD Anderson Cancer Center
-
Danville, Illinois, Forente stater, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Forente stater, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Forente stater, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Forente stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forente stater, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Forente stater, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Forente stater, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Forente stater, 61401
- Illinois CancerCare-Galesburg
-
Glenview, Illinois, Forente stater, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Forente stater, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Forente stater, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Forente stater, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Forente stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Forente stater, 60153
- Loyola University Medical Center
-
Mount Vernon, Illinois, Forente stater, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Forente stater, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Forente stater, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Forente stater, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forente stater, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Forente stater, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Forente stater, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Forente stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forente stater, 62702
- Springfield Clinic
-
Urbana, Illinois, Forente stater, 61801
- Carle Cancer Center
-
Washington, Illinois, Forente stater, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46237
- Franciscan Health Indianapolis
-
Indianapolis, Indiana, Forente stater, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Forente stater, 46219
- Community Cancer Center East
-
Indianapolis, Indiana, Forente stater, 46227
- Community Cancer Center South
-
Indianapolis, Indiana, Forente stater, 46256
- Community Cancer Center North
-
Kokomo, Indiana, Forente stater, 46904
- Community Howard Regional Health
-
Lafayette, Indiana, Forente stater, 47905
- Franciscan Saint Elizabeth Health - Lafayette East
-
Michigan City, Indiana, Forente stater, 46360
- Woodland Cancer Care Center
-
Mooresville, Indiana, Forente stater, 46158
- Franciscan Health Mooresville
-
Terre Haute, Indiana, Forente stater, 47804
- Union Hospital
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Forente stater, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Forente stater, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Boone, Iowa, Forente stater, 50036
- McFarland Clinic - Boone
-
Cedar Rapids, Iowa, Forente stater, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, Forente stater, 52403
- Oncology Associates at Mercy Medical Center
-
Clive, Iowa, Forente stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forente stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Forente stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forente stater, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Forente stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forente stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Forente stater, 50501
- McFarland Clinic - Trinity Cancer Center
-
Fort Dodge, Iowa, Forente stater, 50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City, Iowa, Forente stater, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson, Iowa, Forente stater, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Forente stater, 50158
- McFarland Clinic - Marshalltown
-
West Des Moines, Iowa, Forente stater, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Hays, Kansas, Forente stater, 67601
- HaysMed
-
Lawrence, Kansas, Forente stater, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Forente stater, 66061
- The University of Kansas Cancer Center - Olathe
-
Salina, Kansas, Forente stater, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Forente stater, 66606
- University of Kansas Health System Saint Francis Campus
-
Westwood, Kansas, Forente stater, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita, Kansas, Forente stater, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Forente stater, 67214
- Cancer Center of Kansas - Wichita
-
-
Kentucky
-
Bardstown, Kentucky, Forente stater, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Lexington, Kentucky, Forente stater, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Forente stater, 40503
- Baptist Health Lexington
-
Lexington, Kentucky, Forente stater, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Louisville, Kentucky, Forente stater, 40202
- Norton Hospital Pavilion and Medical Campus
-
Louisville, Kentucky, Forente stater, 40241
- Norton Brownsboro Hospital and Medical Campus
-
Louisville, Kentucky, Forente stater, 40217
- Norton Audubon Hospital and Medical Campus
-
-
Louisiana
-
Kenner, Louisiana, Forente stater, 70065
- Ochsner Medical Center Kenner
-
New Orleans, Louisiana, Forente stater, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Augusta, Maine, Forente stater, 04330
- Harold Alfond Center for Cancer Care
-
Bangor, Maine, Forente stater, 04401
- Eastern Maine Medical Center
-
Belfast, Maine, Forente stater, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Forente stater, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer, Maine, Forente stater, 04412
- Lafayette Family Cancer Center-EMMC
-
Rockport, Maine, Forente stater, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Forente stater, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
South Portland, Maine, Forente stater, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21244
- Kaiser Permanente-Woodlawn Medical Center
-
Easton, Maryland, Forente stater, 21601
- University of Maryland Shore Medical Center at Easton
-
Gaithersburg, Maryland, Forente stater, 20879
- Kaiser Permanente-Gaithersburg Medical Center
-
Largo, Maryland, Forente stater, 20774
- Kaiser Permanente - Largo Medical Center
-
Lutherville, Maryland, Forente stater, 21093
- Kaiser Permanente Lutherville - Timonium Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Dana-Farber Cancer Institute
-
Lowell, Massachusetts, Forente stater, 01854
- Lowell General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Bay City, Michigan, Forente stater, 48706
- McLaren Cancer Institute-Bay City
-
Bloomfield, Michigan, Forente stater, 48302
- McLaren Cancer Institute-Bloomfield
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Forente stater, 48114
- Trinity Health Medical Center - Brighton
-
Brownstown, Michigan, Forente stater, 48183
- Henry Ford Cancer Institute-Downriver
-
Canton, Michigan, Forente stater, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Forente stater, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Forente stater, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Forente stater, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Forente stater, 48346
- McLaren Cancer Institute-Clarkston
-
Clarkston, Michigan, Forente stater, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Forente stater, 48346
- Newland Medical Associates-Clarkston
-
Clinton Township, Michigan, Forente stater, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Forente stater, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, Forente stater, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Forente stater, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Forente stater, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Forente stater, 48532
- McLaren Cancer Institute-Flint
-
Flint, Michigan, Forente stater, 48532
- Singh and Arora Hematology Oncology PC
-
Grand Rapids, Michigan, Forente stater, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Jackson, Michigan, Forente stater, 49201
- Allegiance Health
-
Kalamazoo, Michigan, Forente stater, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, Forente stater, 48910
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Lansing, Michigan, Forente stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Lapeer, Michigan, Forente stater, 48446
- McLaren Cancer Institute-Lapeer Region
-
Livonia, Michigan, Forente stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Forente stater, 48154
- Hope Cancer Clinic
-
Mount Clemens, Michigan, Forente stater, 48043
- McLaren Cancer Institute-Macomb
-
Mount Pleasant, Michigan, Forente stater, 48858
- McLaren Cancer Institute-Central Michigan
-
Novi, Michigan, Forente stater, 48377
- Henry Ford Medical Center-Columbus
-
Petoskey, Michigan, Forente stater, 49770
- McLaren Cancer Institute-Northern Michigan
-
Pontiac, Michigan, Forente stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Forente stater, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Port Huron, Michigan, Forente stater, 48060
- McLaren-Port Huron
-
Saginaw, Michigan, Forente stater, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Forente stater, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Forente stater, 48764
- MyMichigan Medical Center Tawas
-
Traverse City, Michigan, Forente stater, 49684
- Munson Medical Center
-
West Bloomfield, Michigan, Forente stater, 48322
- Henry Ford West Bloomfield Hospital
-
West Branch, Michigan, Forente stater, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Forente stater, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Forente stater, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Forente stater, 55337
- Minnesota Oncology - Burnsville
-
Deer River, Minnesota, Forente stater, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Forente stater, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, Forente stater, 55746
- Essentia Health Hibbing Clinic
-
Maplewood, Minnesota, Forente stater, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Forente stater, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Forente stater, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Forente stater, 55454
- Health Partners Inc
-
Saint Paul, Minnesota, Forente stater, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Forente stater, 55102
- United Hospital
-
Sandstone, Minnesota, Forente stater, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Forente stater, 55792
- Essentia Health Virginia Clinic
-
-
Mississippi
-
Grenada, Mississippi, Forente stater, 38901
- Baptist Cancer Center-Grenada
-
New Albany, Mississippi, Forente stater, 38652
- Baptist Memorial Hospital and Cancer Center-Union County
-
Oxford, Mississippi, Forente stater, 38655
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Southhaven, Mississippi, Forente stater, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Ballwin, Missouri, Forente stater, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Cape Girardeau, Missouri, Forente stater, 63703
- Saint Francis Medical Center
-
Columbia, Missouri, Forente stater, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Joplin, Missouri, Forente stater, 64804
- Freeman Health System
-
Joplin, Missouri, Forente stater, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Forente stater, 64108
- University Health Truman Medical Center
-
St Louis, Missouri, Forente stater, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Forente stater, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Anaconda, Montana, Forente stater, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Forente stater, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Forente stater, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Forente stater, 59405
- Great Falls Clinic
-
Great Falls, Montana, Forente stater, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Forente stater, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Forente stater, 59901
- Logan Health Medical Center
-
Missoula, Montana, Forente stater, 59804
- Community Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Forente stater, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Forente stater, 89183
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Forente stater, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Manchester, New Hampshire, Forente stater, 03104
- Dartmouth Cancer Center - Manchester/ DCC Manchester
-
Nashua, New Hampshire, Forente stater, 03063
- Dartmouth Cancer Center - Nashua
-
-
New Jersey
-
Hamilton, New Jersey, Forente stater, 08690
- The Cancer Institute of New Jersey Hamilton
-
Morristown, New Jersey, Forente stater, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Forente stater, 08903
- Rutgers Cancer Institute of New Jersey
-
Paramus, New Jersey, Forente stater, 07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood, New Jersey, Forente stater, 07450
- Valley Health System Ridgewood Campus
-
Somerville, New Jersey, Forente stater, 08876
- Robert Wood Johnson University Hospital Somerset
-
Summit, New Jersey, Forente stater, 07902
- Overlook Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87106
- University of New Mexico Cancer Center
-
Albuquerque, New Mexico, Forente stater, 87110
- Presbyterian Kaseman Hospital
-
Las Cruces, New Mexico, Forente stater, 88011
- Memorial Medical Center-Las Cruces
-
Rio Rancho, New Mexico, Forente stater, 87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Buffalo, New York, Forente stater, 14263
- Roswell Park Cancer Institute
-
Elmira, New York, Forente stater, 14905
- Arnot Ogden Medical Center/Falck Cancer Center
-
Lake Success, New York, Forente stater, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Forente stater, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Forente stater, 14642
- University of Rochester
-
White Plains, New York, Forente stater, 10601
- Dickstein Cancer Treatment Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Clinton, North Carolina, Forente stater, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Forente stater, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville, North Carolina, Forente stater, 28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville, North Carolina, Forente stater, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Kenansville, North Carolina, Forente stater, 28349
- ECU Health Oncology Kenansville
-
Kinston, North Carolina, Forente stater, 28501
- ECU Health Oncology Kinston
-
Pinehurst, North Carolina, Forente stater, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Richlands, North Carolina, Forente stater, 28574
- ECU Health Oncology Richlands
-
Winston-Salem, North Carolina, Forente stater, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, Forente stater, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Forente stater, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Forente stater, 58122
- Sanford Broadway Medical Center
-
Grand Forks, North Dakota, Forente stater, 58201
- Altru Cancer Center
-
-
Ohio
-
Akron, Ohio, Forente stater, 44307
- Cleveland Clinic Akron General
-
Belpre, Ohio, Forente stater, 45714
- Strecker Cancer Center-Belpre
-
Centerville, Ohio, Forente stater, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Forente stater, 45459
- Dayton Physicians LLC-Miami Valley South
-
Chillicothe, Ohio, Forente stater, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, Forente stater, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Forente stater, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Forente stater, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Forente stater, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Forente stater, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Forente stater, 43228
- Doctors Hospital
-
Columbus, Ohio, Forente stater, 43213
- Mount Carmel East Hospital
-
Columbus, Ohio, Forente stater, 43215
- Grant Medical Center
-
Columbus, Ohio, Forente stater, 43222
- Mount Carmel Health Center West
-
Dayton, Ohio, Forente stater, 45409
- Miami Valley Hospital
-
Delaware, Ohio, Forente stater, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Forente stater, 43015
- Grady Memorial Hospital
-
Kettering, Ohio, Forente stater, 45409
- Greater Dayton Cancer Center
-
Lancaster, Ohio, Forente stater, 43130
- Fairfield Medical Center
-
Mansfield, Ohio, Forente stater, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Mansfield, Ohio, Forente stater, 44903
- OhioHealth Mansfield Hospital
-
Marietta, Ohio, Forente stater, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, Forente stater, 43302
- OhioHealth Marion General Hospital
-
Mayfield Heights, Ohio, Forente stater, 44124
- Hillcrest Hospital Cancer Center
-
Mount Vernon, Ohio, Forente stater, 43050
- Knox Community Hospital
-
Newark, Ohio, Forente stater, 43055
- Licking Memorial Hospital
-
Portsmouth, Ohio, Forente stater, 45662
- Southern Ohio Medical Center
-
Sandusky, Ohio, Forente stater, 44870
- North Coast Cancer Care
-
Sylvania, Ohio, Forente stater, 43560
- ProMedica Flower Hospital
-
Warrensville Heights, Ohio, Forente stater, 44122
- South Pointe Hospital
-
West Chester, Ohio, Forente stater, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westerville, Ohio, Forente stater, 43081
- Saint Ann's Hospital
-
Zanesville, Ohio, Forente stater, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Lawton, Oklahoma, Forente stater, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Forente stater, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Forente stater, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
Tulsa, Oklahoma, Forente stater, 74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Bend, Oregon, Forente stater, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Forente stater, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Forente stater, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Forente stater, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Forente stater, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City, Oregon, Forente stater, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Forente stater, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Forente stater, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown, Pennsylvania, Forente stater, 18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem, Pennsylvania, Forente stater, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Bethlehem, Pennsylvania, Forente stater, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Easton, Pennsylvania, Forente stater, 18045
- Saint Luke's Hospital-Anderson Campus
-
Erie, Pennsylvania, Forente stater, 16544
- Saint Vincent Hospital
-
Harrisburg, Pennsylvania, Forente stater, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Jefferson Hills, Pennsylvania, Forente stater, 15025
- Jefferson Hospital
-
Monroeville, Pennsylvania, Forente stater, 15146
- Forbes Hospital
-
Natrona Heights, Pennsylvania, Forente stater, 15065
- Allegheny Valley Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- UPMC Hillman Cancer Center
-
Quakertown, Pennsylvania, Forente stater, 18951
- Saint Luke's Hospital-Quakertown Campus
-
West Reading, Pennsylvania, Forente stater, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Forente stater, 15090
- Wexford Health and Wellness Pavilion
-
Willow Grove, Pennsylvania, Forente stater, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Anderson, South Carolina, Forente stater, 29621
- AnMed Health Cancer Center
-
Beaufort, South Carolina, Forente stater, 29902
- Beaufort Memorial Hospital
-
Boiling Springs, South Carolina, Forente stater, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Forente stater, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Forente stater, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Forente stater, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Forente stater, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Forente stater, 29601
- Saint Francis Hospital
-
Greer, South Carolina, Forente stater, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Forente stater, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, Forente stater, 29303
- Spartanburg Medical Center
-
-
South Dakota
-
Aberdeen, South Dakota, Forente stater, 57401
- Avera Cancer Institute-Aberdeen
-
Sioux Falls, South Dakota, Forente stater, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Forente stater, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Forente stater, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Bristol, Tennessee, Forente stater, 37620
- Bristol Regional Medical Center
-
Collierville, Tennessee, Forente stater, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Cookeville, Tennessee, Forente stater, 38501
- Cookeville Regional Medical Center
-
Johnson City, Tennessee, Forente stater, 37604
- Wellmont Medical Associates Oncology and Hematology-Johnson City
-
Kingsport, Tennessee, Forente stater, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Forente stater, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Memphis, Tennessee, Forente stater, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Amarillo, Texas, Forente stater, 79106
- The Don and Sybil Harrington Cancer Center
-
Beaumont, Texas, Forente stater, 77701
- Baptist Hospitals of Southeast Texas Cancer Center
-
Conroe, Texas, Forente stater, 77384
- UT MD Anderson - The Woodlands
-
Dallas, Texas, Forente stater, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Forente stater, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Edinburg, Texas, Forente stater, 78539
- STCC at DHR Health Institute for Research and Development
-
Houston, Texas, Forente stater, 77026-1967
- Lyndon Baines Johnson General Hospital
-
Houston, Texas, Forente stater, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Forente stater, 77030
- Houston Methodist Hospital
-
Houston, Texas, Forente stater, 77079
- UT MD Anderson - West Houston
-
League City, Texas, Forente stater, 77573
- UT MD Anderson - League City
-
Port Arthur, Texas, Forente stater, 77642
- Baptist Regional Cancer Network-Cancer Center of Southeast Texas
-
Sugar Land, Texas, Forente stater, 77478
- UT MD Anderson - Sugar Land
-
Temple, Texas, Forente stater, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Vermont
-
Saint Johnsbury, Vermont, Forente stater, 05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Bristol, Virginia, Forente stater, 24201
- Ballad Health Cancer Care - Bristol
-
Burke, Virginia, Forente stater, 22015
- Kaiser Permanente-Burke Medical Center
-
Fishersville, Virginia, Forente stater, 22939
- Augusta Health Center for Cancer and Blood Disorders
-
Lynchburg, Virginia, Forente stater, 24501
- Centra Alan B Pearson Regional Cancer Center
-
McLean, Virginia, Forente stater, 22102
- Kaiser Permanente Tysons Corner Medical Center
-
Norton, Virginia, Forente stater, 24273
- Ballad Health Cancer Care - Norton
-
Richmond, Virginia, Forente stater, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Forente stater, 23229
- Virginia Cancer Institute
-
Richmond, Virginia, Forente stater, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Forente stater, 23970
- VCU Community Memorial Health Center
-
Woodbridge, Virginia, Forente stater, 22192
- Kaiser Permanente-Caton Hill Medical Center
-
-
Washington
-
Edmonds, Washington, Forente stater, 98026
- Swedish Cancer Institute-Edmonds
-
Issaquah, Washington, Forente stater, 98029
- Swedish Cancer Institute-Issaquah
-
Port Townsend, Washington, Forente stater, 98368
- Jefferson Healthcare
-
Seattle, Washington, Forente stater, 98122
- Swedish Medical Center-First Hill
-
Spokane, Washington, Forente stater, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane, Washington, Forente stater, 99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
-
West Virginia
-
Charleston, West Virginia, Forente stater, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown, West Virginia, Forente stater, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, Forente stater, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Antigo, Wisconsin, Forente stater, 54409
- Aspirus Cancer Care-Antigo-Volm Cancer Center
-
Appleton, Wisconsin, Forente stater, 54911
- ThedaCare Regional Cancer Center
-
Appleton, Wisconsin, Forente stater, 54915
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
-
Ashland, Wisconsin, Forente stater, 54806
- Duluth Clinic Ashland
-
Brookfield, Wisconsin, Forente stater, 53045
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
-
Eau Claire, Wisconsin, Forente stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
Franklin, Wisconsin, Forente stater, 53132
- Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
-
Green Bay, Wisconsin, Forente stater, 54301
- Bellin Memorial Hospital
-
Janesville, Wisconsin, Forente stater, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Johnson Creek, Wisconsin, Forente stater, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
La Crosse, Wisconsin, Forente stater, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Forente stater, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Forente stater, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Medical Center-Marshfield
-
Medford, Wisconsin, Forente stater, 54451
- Aspirus Medford Hospital
-
Minocqua, Wisconsin, Forente stater, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Forente stater, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Forente stater, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Forente stater, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh, Wisconsin, Forente stater, 54904
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
-
Racine, Wisconsin, Forente stater, 53405
- Ascension All Saints Hospital-Spring Street-Racine
-
Rhinelander, Wisconsin, Forente stater, 54501
- Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
-
Rice Lake, Wisconsin, Forente stater, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Forente stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Forente stater, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Forente stater, 53188
- ProHealth Waukesha Memorial Hospital
-
Wausau, Wisconsin, Forente stater, 54401
- Aspirus Cancer Care-Wausau
-
Wauwatosa, Wisconsin, Forente stater, 53226
- Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
-
Weston, Wisconsin, Forente stater, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Forente stater, 54494
- Aspirus Cancer Care - Wisconsin Rapids
-
-
Wyoming
-
Cheyenne, Wyoming, Forente stater, 82001
- Cheyenne Regional Medical Center-West
-
Cody, Wyoming, Forente stater, 82414
- Billings Clinic-Cody
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
-
Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer except for one cycle of FOLFOX or capecitabine and oxaliplatin (CAPOX), either with or without bevacizumab prior to enrollment. Upon enrollment, the preceding single cycle of FOLFOX or FOLFOX + bevacizumab, if the patient received one, will not count towards patients' assessments per protocol. Cycle 1 day 1 (C1D1) of atezolizumab or C1D1 of mFOLFOX6/bevacizumab + atezolizumab will correspond to the first day the patient received therapy on trial
-
Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory Improvement Act (CLIA)-certified immunohistochemical (IHC) assay with a panel of all four IHC markers, including MLH1, MSH2, PMS2, and MSH6; alternatively, MSI-H diagnosed by polymerase chain reaction (PCR)-based assessment of microsatellite alterations (either Bethesda markers or Pentaplex panel) or by next-generation sequencing (NGS) are eligible
-
Documentation by PET/CT scan, CT scan, or MRI that the patient has measurable metastatic disease per RECIST 1.1
-
No immediate need for surgical intervention for the primary tumor or palliative diversion/bypass
-
Absolute neutrophil count (ANC) must be >= 1500/mm^3 (obtained within 28 days prior randomization)
-
Platelet count must be >= 100,000/mm^3 (obtained within 28 days prior randomization)
-
Hemoglobin must be >= 8 g/dL (obtained within 28 days prior randomization)
-
Total bilirubin must be =< 4 x ULN (upper limit of normal) (obtained within 28 days prior randomization); and
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN (obtained within 28 days prior randomization)
-
Calculated creatinine clearance >= 30 mL/min (obtained within 28 days prior randomization)
-
A urine sample tested for proteinuria by either the dipstick method, urinalysis (UA), or a urine protein creatinine (UPC) ratio:
- The dipstick method must indicate 0-1+ protein; if dipstick reading is >= 2+, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
- A urine protein creatinine (UPC) ratio must be < 1.0; if the UPC ratio is >= 1.0 a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours
- Urinalysis must indicate < 30 mg/dl. If urinalysis >= 30 mg/dl, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
-
International normalized ratio of prothrombin time (INR) and prothrombin time (PT) must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history, regardless of PT/INR results
-
Pregnancy test done within 28 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; administration of atezolizumab or mFOLFOX6/bevacizumab/atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
-
Women of child-bearing potential and men must agree to use adequate contraception methods that result in a failure rate of < 1% per year during the treatment period (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6; a woman is considered to be of childbearing potential if she is not postmenopausal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus); examples of contraceptive methods with a failure rate of < 1% per year include: bilateral tubal ligation; male partner sterilization; intrauterine devices; the reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception; men must refrain from donating sperm during this same period
Exclusion Criteria:
-
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin
-
Uncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 100 mmHg with or without anti-hypertensive medication; patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria
-
Documented New York Heart Association (NYHA) class III or IV congestive heart failure
-
Serious or non-healing wound, skin ulcer, or bone fracture
-
History of inherited bleeding diathesis, gastrointestinal (GI) perforation, significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis or symptomatic peripheral ischemia, transient ischemic attack [TIA], cerebrovascular accident [CVA] or arterial thrombotic event), abdominal fistula, intra-abdominal abscess, or active GI bleeding (with cause not addressed) within 6 months prior to randomization, or other medical condition in the opinion of the treating oncologist that makes the risk of cardiovascular or bleeding complications with bevacizumab use unacceptably high
-
Other malignancies are excluded unless the patient has completed therapy for the malignancy >= 12 months prior to randomization and is considered disease-free; patients with the following cancers are eligible if diagnosed and treated within the past 12 months: in situ carcinomas or basal cell and squamous cell carcinoma of the skin
-
Known DPD (dihydro pyrimidine dehydrogenase) deficiency
-
Symptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0)
-
Prior treatment with oxaliplatin chemotherapy within 6 months prior to randomization
-
History of grade 2 hemoptysis (defined as 2.5 mL of bright red blood per episode) within 1 month prior to screening
-
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4 may be enrolled provided the following requirements are met:
- Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization
- No history of severe immune-related adverse effects (CTCAE grade 3 and 4) from anti-CTLA-4
-
Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization; however,
- Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea; or chronic daily treatment with corticosteroids with a dose of =< 10 mg/day methylprednisolone equivalent) may be enrolled
- The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
-
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; however,
- Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HbsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible if polymerase chain reaction (PCR) for hepatits B virus (HBV) ribonucleic acid (RNA) is negative per local guidelines
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA per local guidelines
-
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; however,
-
Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible
-
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible
-
Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
- Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
- Rash must cover less than 10% of body surface area (BSA)
- Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
- No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
-
-
History of idiopathic pulmonary fibrosis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or active or recently active (within 90 days of randomization) pneumonitis (including drug induced) that required systemic immunosuppressive therapy (i.e. corticosteroids, etc.). History of radiation pneumonitis in the radiation field (fibrosis) is permitted
-
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
-
Patients with known active tuberculosis (TB) are excluded
-
Severe infections within 28 days prior to randomization, including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
-
Signs or symptoms of infection within 14 days prior to randomization
-
Received oral or intravenous (IV) antibiotics within 14 days prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
-
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study
-
The administration of a live, attenuated vaccine within 28 days prior to randomization
-
Pregnant women are excluded from this study because atezolizumab is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, breastfeeding should be discontinued if the mother is treated with atezolizumab; these potential risks may also apply to other agents used in this study; (Note: pregnancy testing should be performed within 28 days prior to randomization according to institutional standards for women of childbearing potential)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Arm I (bevacizumab, mFOLFOX6)
Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL) |
Ancillary studies
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
Undergo MRI
Andre navn:
Ancillary studies Undergo collection of blood samples
Andre navn:
Given IV
Andre navn:
Undergo CT or CT/PET
Andre navn:
Given IV
Andre navn:
Undergo CT/PET
Andre navn:
|
|
Eksperimentell: Arm II (atezolizumab)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
Andre navn:
Undergo MRI
Andre navn:
Ancillary studies Undergo collection of blood samples
Andre navn:
Given IV
Andre navn:
Undergo CT or CT/PET
Andre navn:
Undergo CT/PET
Andre navn:
|
|
Eksperimentell: Arm III (atezolizumab, bevacizumab, mFOLFOX6)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
Undergo MRI
Andre navn:
Ancillary studies Undergo collection of blood samples
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
Undergo CT or CT/PET
Andre navn:
Given IV
Andre navn:
Undergo CT/PET
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression free survival (PFS)
Tidsramme: From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
The analysis set is intent-to-treat (ITT). The experimental arms will be compared to the control arm by the log-rank test stratified by BRAF status (V600E mutation or not), metastatic disease: (liver-only, extra-hepatic), and prior adjuvant therapy for colon cancer (yes, no). Hazard ratios and associated confidence intervals from a stratified Cox regression model will also be reported along with estimates of the distributions of time to PFS event by the method of Kaplan and Meier. Sensitivity analyses accounting for 2 or more consecutively missed scheduled tumor imaging scans before progression/death will also be conducted. |
From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sats på PFS
Tidsramme: Ved 12 måneder
|
Ved 12 måneder
|
|
|
Overall survival (OS)
Tidsramme: The time from randomization to death from any cause, assessed up to 5 years
|
Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
The time from randomization to death from any cause, assessed up to 5 years
|
|
Objective response rate (ORR) (complete response [CR] or partial response [PR])
Tidsramme: Up to 5 years
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemotherapy [chemo]) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
Up to 5 years
|
|
Incidence of adverse events
Tidsramme: Up to 30 days after last cycle
|
Defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The safety profile will be described by tabulating the maximum observed grade of adverse event for each individual adverse event, for each system organ class, and overall using the Safety population. |
Up to 30 days after last cycle
|
|
Disease control rate (CR + PR + stable disease [SD])
Tidsramme: At 12 months
|
Assessed by RECIST 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemo) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
At 12 months
|
|
Duration of overall response (CR or PR)
Tidsramme: From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed by RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
|
Duration of SD
Tidsramme: From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed per RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Severity of fatigue
Tidsramme: At 16 weeks
|
Will use the ITT population. Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue questionnaire. Will be compared between the control arm (Chemo-bevacizumab [Bev]) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Physical functioning
Tidsramme: At 16 weeks
|
Will use the ITT population. Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire (QLQ)-C30 physical functioning scale. Will be compared between the control arm (Chemo-Bev) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Health utility scores
Tidsramme: Up to 5 years
|
Will use the ITT population. Will be measured using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire. |
Up to 5 years
|
|
Proportion of patients reporting each response option at each assessment timepoint by treatment arm for item GP5 from the Functional Assessment of Cancer Therapy - General (FACT-G)
Tidsramme: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Intratumoral lymphocyte PD-L1+ expression (>= 1 % is positive) by immunohistochemistry (IHC) as a predictive biomarker of efficacy
Tidsramme: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy dependent on the number of somatic mutations
Tidsramme: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy in tumors with MLH1 silencing
Tidsramme: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Change in quantification of cell free deoxyribonucleic acid (cfDNA) mutations
Tidsramme: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
Development of progression or relapse to treatment in cfDNA
Tidsramme: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Changes in T-cell repertoire diversity as a predictive biomarker of efficacy
Tidsramme: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
PFS of patients with high levels of diversity
Tidsramme: Up to 5 years
|
Compared to patients with low levels of diversity. Will use the ITT population. |
Up to 5 years
|
|
Change in T-cell diversity
Tidsramme: Baseline to first restaging between immunotherapy arms and the standard of care arm
|
Will use the ITT population. |
Baseline to first restaging between immunotherapy arms and the standard of care arm
|
|
Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected
Tidsramme: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Caio Max S Rocha Lima, NRG Oncology
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Antatt)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Tarmsykdommer
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Kolonsykdommer
- Kolorektale neoplasmer
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Undersøkelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Enzymer og koenzymer
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Uorganiske kjemikalier
- Koordinasjonskomplekser
- Pyrimidiner
- Kjemisteknikker, analytisk
- Spektrumanalyse
- Formyltetrahydrofolater
- Tetrahydrofolater
- Folsyre
- Pteriner
- Pteridiner
- Uracil
- Pyrimidinoner
- Koenzymer
- Immunoglobulinisotyper
- Sulfider
- Anioner
- Ioner
- Elektrolytter
- Hydrogensulfid
- Oksaliplatin
- Bevacizumab
- Fluorouracil
- Leucovorin
- Immunoglobulin G
- Prøvehåndtering
- Magnetisk resonansspektroskopi
- Disulfider
- Atezolizumab
- Dehydroftorafur
Andre studie-ID-numre
- NCI-2016-01961
- U10CA180868 (U.S. NIH-stipend/kontrakt)
- NCI-2016-01961 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- NRG-GI004/S1610
- NRG-GI004 (Annen identifikator: CTEP)
- NRG-GI004 (Annen identifikator: NRG Oncology)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .